An Efficacy and Safety Study of Oral Osmotic Therapeutic System (OROS) Hydromorphone Hydrochloride (HCl) in Participants With Cancer Related Pain
Condition: Pain
Study type: Interventional
Phase: Phase 3

Summary: 
      The purpose of this study is to compare the safety and efficacy of Oral Osmotic Therapeutic
      System (OROS) hydromorphone hydrochloride (HCl) with controlled-release oxycodone HCl in
      participants with cancer-related pain.
    

Detailed description: 
      This is a double-blind (a medical research study in which neither the researchers nor the
      participants know what treatment the participants is receiving), randomized (study drug is
      assigned by chance), multi-center (when more than one hospital or medical school team work on
      a medical research study), comparative, parallel-group (a clinical trial comparing the
      response in two or more groups of participants receiving different treatments) study of OROS
      hydromorphone HCl compared with oxycodone HCl controlled-release in participants with
      moderate to severe cancer (abnormal tissue that grows and spreads in the body until it kills)
      pain. The study will consist of 3 phases: a screening period (up to 14 days before
      randomization), a dose titration phase (up to 8 days), and a dose maintenance phase (28
      days). The study visits will be scheduled at weekly intervals. Eligible participants will be
      randomly assigned to receive either hydromorphone HCl once daily or oxycodone HCl twice daily
      (placebo will be administered when necessary for blinding). During titration phase, dosage of
      hydromorphone HCl or oxycodone HCl will be adjusted upward or downward to achieve stable pain
      control. It can be from 2 days to 8 days. Participants who complete dose titration will enter
      into the dose maintenance phase and will receive study treatment for 28 consecutive days.
      Morphine hydrochloride will be given as rescue analgesic (drug used to control pain)
      medication for breakthrough pain during the study. Primarily efficacy will be evaluated by
      measuring change in the score of Brief Pain Inventory (BPI) questionnaire item 'worst pain'
      at end of maintenance period. Participants' safety will be monitored throughout the study.
    

Intervention name(s): Hydromorphone HCl; Oxycodone HCl CR; Placebo
Intervention type(s): Drug; Drug; Drug
Intervention description(s): Hydromorphone HCl will be administered in dose of 8, 16, 24, and 32 milligram (mg), once daily for 2 to 8 days of Titration phase and 28 days of Maintenance phase. Starting dose will be based on participant's previous daily opioid dose.; Oxycodone HCl will be administered in dose of 10, 20, 30 and 40 mg, twice daily for 2 to 8 days of titration phase and 28 days of maintenance phase. Starting dose will be based on participant's previous daily opioids dose.; Placebo will be administered to the participants receiving hydromorphone HCl or oxycodone HCl CR along with the study treatment to maintain necessary blinding.
Intervention MeSH terms: Oxycodone; Hydromorphone
Allocation: Randomized
Intervention model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary purpose: Treatment
Keywords: Pain; Hydromorphone hydrochloride; Oxycodone hydrochloride